Testing MTM-H-001 injection for B-cell autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new injection called MTM-H-001 to treat autoimmune diseases where the body's B cells attack itself (like rheumatoid arthritis or lupus). The trial aims to see if this treatment is safe and effective for adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have been diagnosed with a B-cell autoimmune disease (confirmed by standard medical tests)
- Your organs (kidney, liver, heart, etc.) are healthy enough to handle the treatment
- You are not pregnant, not planning to become pregnant during the study, and not breastfeeding
- You do not have a serious active infection that is not under control
- You have not had cancer in the past (except low-risk types that were fully treated)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
This trial tests a new injection, MTM-H-001, in adults whose B-cell lymphoma has returned or not responded after at least two prior treatments. The goal is to see if it can help control the cancer.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.